An update on pharmacological approaches to neurodegenerative diseases

Bibliography

• PRUSINER EB: Neurodegenerative diseases and prions. N. Eng. J. Med. (2001) 344:1516-1526.
   PubMed Web of Science ®Google Scholar
• HILBUSH BS, MORRISON JH, YOUNG WG et al. New prospects and strategies for drug target discovery in neurodegenerative disorders. NeuroRx (2005) 2:627-637.
   PubMedGoogle Scholar
• BOSSY-WETZEL E, SCHWARZENBACHER R, LIPTON SA: Molecular pathway to neurodegeneration. Nat. Med. (2004) 10:S2-S9 (Supplement).
   PubMed Web of Science ®Google Scholar
• ROSS AC, POIRIER LA: Protein aggregation and neurodegenerative disease. Nat. Med. (2004) 10:S10-S17 (Supplement).
   PubMed Web of Science ®Google Scholar
• WEISSMANN C: The state of the prion. Nat. Rev. Microbiol. (2004) 2:861-871.
   PubMed Web of Science ®Google Scholar
• CASHMAN NR, CAUGHEY B: Prion diseases-close to effective therapy? Nat. Rev. Drug Discov. (2004) 3:874-884.
   PubMed Web of Science ®Google Scholar
• ROSS AC, POIRIER LA: What is the role of protein aggregation in neurodegeneration? Nat. Rev. Mol. Cell Biol. (2005) 6:891-898.
   PubMed Web of Science ®Google Scholar
• VARDY RLC E, CATTO AJ, HOOPER NM: Proteolytic mechanisms in amyloid-β metabolism: therapeutic implications for Alzheimer’s disease. Trends Mol. Med. (2005) 11:464-472.
   PubMed Web of Science ®Google Scholar
• BEHER D, GRAHAM SL: Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease. Expert Opin. Investig. Drugs (2005) 14(11):1385-409.
   Google Scholar
• CITRON M: Strategies for disease modification in Alzheimer disease. Nat. Rev. Neur. (2004) 5:677-685.
   Google Scholar
• LANSBURY PT: Back to the future: the 'old-fashioned' way to new medications for neurodegeneration. Nat. Med. (2004) 10:S51-S57 (Supplement).
   PubMed Web of Science ®Google Scholar
• MARTINEZ A, CASTRO A: Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease. Expert Opin. Investig. Drugs (2006) 15(1):1-12.
   Google Scholar
• GOZES I, SPIVAK-POHIS I: Neurotrophic effects of the peptide NAP: a novel neuroprotective drug candidate. Curr. Alzheimer Res. (2006) 3:197-199.
   Web of Science ®Google Scholar
• SARI Y, GOZES I. Brain deficits associated with fetal alcohol exposure may be protected, in part, by peptides derived from activity-dependent neurotrophic factor and activity-dependent neuroprotective protein. Brain Res Brain Res Rev (2006) 52:107-118.
   PubMed Web of Science ®Google Scholar
• KWON MO, HERRLING P: List of drugs in development for neurodegenerative diseases. Neurodegenerative Dis. (2005) 2:61-108.
   PubMed Web of Science ®Google Scholar
• BIRMINGHAM K: Future of neuroprotective drugs in doubt. Nat. Med. (2002) 8:5.
   PubMedGoogle Scholar
• SMALL DH: Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer's disease: do we need new inhibitors? Expert Opin. Emerg. Drugs (2005) 10(4):817-825.
   PubMedGoogle Scholar
• WOLFE MS: Therapeutic strategies for Alzheimer's disease. Nat. Rev. Drug Discov. (2002) 1:859-866.
   PubMed Web of Science ®Google Scholar
• SCARPINI E, SCHELTENS P, FELDMAN H: Treatment of Alzheimer’s disease: current status and new perspectives. Lancet Neurol. (2003) 2:539-547.
   PubMed Web of Science ®Google Scholar
• CHALIFOUR RJ, McLAUGHLIN RW, LAVOIE L et al.: Stereoselective interactions of peptide inhibitors with the β-amyloid peptide. J. Biol. Chem. (2003) 278:34874-34881.
   PubMed Web of Science ®Google Scholar
• HUANG TH, YANG DS, PLASKOS NP et al.: Structural studies of soluble oligomers of the Alzheimer β-amyloid peptide. J. Mol. Biol. (2000) 297:73-87.
   PubMed Web of Science ®Google Scholar
• AISEN PS: The development of anti-amyloid therapy for Alzheimer's disease: from secretase modulators to polymerisation inhibitors. CNS Drugs (2005) 19:989-996.
   PubMed Web of Science ®Google Scholar
• RATTRAY M: Technology evaluation: colostrinin, ReGen. Curr. Opin. Mol. Ther. (2005) 7:78-84.
   Web of Science ®Google Scholar
• BILIKIEWICZ A, GAUS W: Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease. J. Alzheimers Dis. (2004) 6:17-26.
   Google Scholar
• LABIE C, CANOLLE B, CHATELIN S et al.: Effects of paliroden (SR57667B) and xaliproden on adult brain neurogenesis. Curr. Alzheimer Res. (2006) 3:35-36.
   Google Scholar
• MEININGER V, BENSIMON G, BRADLEY WR et al.: Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two Phase III trials. Amyotroph. Lateral Scler. Other Motor Neuron Disord. (2004) 5:107-117.
   PubMed Web of Science ®Google Scholar
• IMBIMBO BP: The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease. Expert Opin. Investig. Drugs (2004) 13(11):1469-1481.
   PubMed Web of Science ®Google Scholar
• GASPARINI L, RUSCONI L, XU H et al.: Modulation of β-amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cell cultures. J. Neurochem. (2004) 88:337-348.
   Google Scholar
• GASPARINI L, ONGINI E, WILCOCK D, MORGAN D: Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease. Brain Res. Brain Res. Rev. (2005) 48:400-408.
   PubMed Web of Science ®Google Scholar
• JANTZEN PT, CONNOR KE, DICARLO G et al.: Microglial activation and β-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci. (2002) 22:2246-2254.
   Google Scholar
• GREIG NH, DE MICHELI E, HOLLOWAY HW et al.: The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. Acta Neurol. Scand. Suppl. (2000) 176:74-84.
   Google Scholar
• GREIG NH, SAMBAMURTI K, YU QS, BROSSI A, BRUINSMA GB, LAHIRI DK: An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr. Alzheimer Res. (2005) 2:281-290.
   Web of Science ®Google Scholar
• WILENS TE, VERLINDEN MH, ADLER LA et al.: ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. Biol. Psychiatry (2006) 59(11):1065-1070.
   PubMed Web of Science ®Google Scholar
• RUETER LE, ANDERSON DJ, BRIGGS CA et al.: ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders. CNS Drug Rev. (2004) 10:167-182.
   PubMedGoogle Scholar
• LYNCH G: Glutamate-based therapeutic approach: ampakine. Curr. Opin. Pharmacol. (2006) 6:82-88.
   Web of Science ®Google Scholar
• LINDEN AM, YU H, ZARRINMAYEH H et al.: Binding of an AMPA receptor potentiator ([3H]LY395153) to native and recombinant AMPA receptors. Neuropharmacology (2001) 40:1010-1018.
   PubMed Web of Science ®Google Scholar
• XIA YF, KESSLER M, ARAI AC: Positive α-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid (AMPA) receptor modulators have different impact on synaptic transmissionin the thalamus and hippocampus. J. Pharmacol. Exp. Ther. (2005) 313:277-285.
   Google Scholar
• BACHURIN S, BUKATINA E, LERMONTOVA N et al.: Antihistamine agent dimebon as a novel neuroprotector and a cognition enhancer. Ann. NY Acad. Sci. (2001) 939:425-435.
   PubMed Web of Science ®Google Scholar
• MARUYAMA W, WEINSTOCK M, YOUDIM MB et al.: Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]- ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci. Lett. (2003) 341:233-236.
   Web of Science ®Google Scholar
• FROESTL W, GALLAGHER M, JENKINS H et al.: SGS742, a GABAB receptor antagonist in clinical trial. Biochem. Pharmacol. (2004) 68:1479-1487.
   PubMed Web of Science ®Google Scholar
• HELM KA, HABERMAN RP, DEAN SL et al.: GABA B receptor antagonist SGS742 improves spatial memory and reduces protein binding to the cAMP response element (CRE) in the hippocampus. Neuropharmacology (2005) 48:956-964.
   PubMed Web of Science ®Google Scholar
• MCKERNAN RM, ROSAHL TW, REYNOLDS DS et al.: Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor α1 subtype. (2000) Nat. Neuroscience 3:587-592.
   PubMed Web of Science ®Google Scholar
• COLLINSON N, KUENZI F, JAROLIMEK W et al.: Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the α5 subunit of the GABAA receptor. J. Neurosci. (2002) 22:5572-5580.
   Google Scholar
• SPENCER JP, BROWN JT, RICHARDSON JC et al.: Modulation of hippocampal excitability by 5-HT4 receptor agonists persists in a transgenic model of Alzheimer’s disease. Neuroscience (2004) 129:49-54.
   PubMed Web of Science ®Google Scholar
• DUNBAR G, DEMAZIERES A, MONREAL A et al.: Pharmacokinetics and safety profile of ispronicline (TC-1734), a new brain nicotinic receptor partial agonist, in young healthy male volunteers. J. Clin. Pharmacol. (2006) 46:715-726.
   Google Scholar
• BAYER AJ, BULLOCK R, JONES RW et al.: Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology (2005) 64:94-101.
   PubMed Web of Science ®Google Scholar
• SCHENK D: Amyloid-β immunotherapy for Alzheimer’s disease: the end of the beginning. Nat. Rev. Neuroscience (2002) 3:824-828.
   PubMed Web of Science ®Google Scholar
• GHOCHIKYAN A, MKRTICHYAN M, PETRUSHINA I et al.: Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Aβ antibody response with Alum to Quil A adjuvant switch. Vaccine (2006) 24:2275-2282.
   PubMed Web of Science ®Google Scholar
• LEE EB, LENG LZ, ZHANG B et al.: Targeting amyloid-β peptide (Aβ) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Aβ precursor protein (APP) transgenic mice. J. Biol. Chem. (2006) 281:4292-4299.
   Google Scholar
• LEVITES Y, DAS P, PRICE RW et al.: Anti-Aβ42- and anti-Aβ40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J. Clin. Invest. (2006) 116:193-201
   Google Scholar
• KULIC L, KUROSINSKI P, CHEN F et al.: Active immunization trial in Aβ42-injected P301L tau transgenic mice. Neurobiol. Dis. (2006) 22:50-56.
   Google Scholar
• SIEMERS ER, QUINN JF, KAYE J et al.: Effects of a γ-secretase inhibitor in a randomised study of patients with Alzheimer disease. Neurology (2006) 66:602-604.
   PubMed Web of Science ®Google Scholar
• SIEMERS E, SKINNER M, DEAN RA et al.: Safety, tolerability, and changes in amyloid β concentrations after administration of a γ-secretase inhibitor in volunteers. Clin. Neuropharmacol. (2005) 28:126-132.
   Google Scholar
• WHITE AR, DU T, LAUGHTON KM et al.: Degradation of the Alzheimer disease amyloid β-peptide by metal-dependent up-regulation of metalloprotease activity. J. Biol. Chem. (2006) 281:17670-80
   Google Scholar
• TAKASU T: SMON – a model of the iatrogenic disease. Rinsho Shinkeigaku (2003) 43:866-869.
   PubMedGoogle Scholar
• HUCKLE R. PBT-1 Prana Biotechnology. Curr. Opin. Investig. Drugs (2005) 6:99-107.
   Google Scholar
• BONETTA L: Potential neurological value of statins increases. Nat. Med. (2002) 8:541.
   PubMedGoogle Scholar
• PEDRINI S, CARTER TL, PRENDERGAST G et al.: Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLoS Med. (2005) 2:e18.
   PubMed Web of Science ®Google Scholar
• SPARKS DL, SABBAGH MN, CONNOR DJ et al.: Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. Curr. Alzheimer Res. (2005) 2:343-353.
   Google Scholar
• WATSON GS, CHOLERTON BA, REGER MA et al.: Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry (2005) 13:950-958.
   Web of Science ®Google Scholar
• WATSON GS, CRAFT S: The role of insulin resistance in the pathogenesis of Alzheimer’s disease: implications for treatment. CNS Drugs (2003) 17:27-45.
   PubMed Web of Science ®Google Scholar
• MEETHAL SV, SMITH MA, BOWEN RL et al.: The gonadotropin connection in Alzheimer’s disease. Endocrine (2005) 26:317-329.
   PubMed Web of Science ®Google Scholar
• CASADESUS G, WEBBER KM, ATWOOD CS et al.: Luteinizing hormone modulates cognition and amyloid-β deposition in Alzheimer APP transgenic mice. Biochim. Biophys. Acta (2006) 176(2):447-452.
   Google Scholar
• ABDUL-HAY S, SUTHERLAND JR, REYNOLDS JN et al.: GT 1061, a novel nitrate ester in clinical trials for Alzheimer's disease, enhances cognitive performance in rats with forebrain cholinergic depletion. 37th Great Lakes Regional Meeting Milwaukee, USA (31 May – 2 June 2006):WI 152.
   Google Scholar
• THATCHER GR, BENNET BM, REYNOLDS JS: Nitric oxide mimetic molecules as therapeutic agents in Alzheimer’s disease. Curr. Alzheimer Res. (2005) 2:171-182.
   Google Scholar
• FUKUSHIMA T, KOIDE M, AGO Y et al.: T-817MA, a novel neurotrophic agent, improves sodium nitroprusside-induced mitochondrial dysfunction in cortical neurons. Neurochem. Int. (2006) 48:124-130.
   Google Scholar
• HIRATA K, YAMAGUCHI Y, TAKAGI A et al.: A novel neurotrophic agent, T-817MA [1-3-[2-(1-benzothiophen- 5-yl)ethoxy]propyl-3-azetidinol maleate], attenuates amyloid-β-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons. J. Pharmacol. Exp. Ther. (2005) 314:252-259.
   Google Scholar
• PAUWELS PJ, RAULY I, WURCH T: Dissimilar pharmacological responses by a new series of imidazoline derivatives at precoupled and ligand-activated α2A-adrenoreceptor states: evidence for effector pathway-dependent differential antagonism. J. Pharmacol. Exp. Ther. (2003) 305:1015-1023.
   Google Scholar
• DEBEIR T, MARIEN M, FERRARIO J et al.: In vivo upregulation of endogenous NGF in the rat brain by the α2-adrenoreceptor antagonist dexefaroxan: potential role in the protection of the basolocortical cholinergic system during neurodegeneration. Exp. Neurol. (2004) 190:384-395.
   Google Scholar
• ROCKENSTEIN E, TORRANCE M, MANTE M et al.: Cerebrolysin decreases amyloid-β production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer’s disease. J. Neurosci. Res. (2006) 83:1252-1261.
   Google Scholar
• POTKIN SG, ALVA G, KEATOR D et al.: Brain metabolic effects of Neotrofin in patients with Alzheimer’s disease. Brain Res. (2002) 951:87-95.
   PubMed Web of Science ®Google Scholar
• MATA IF, WEDEMEYER WJ, FARRER MJ et al.: LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. (2006) 29:286-293.
   Google Scholar
• WILLIAMS-GRAY CH, GORIS A, FOLTYNIE T et al.: Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort. J. Neurol. Neurosurg. Psychiatry (2006) 77:665-667.
   PubMed Web of Science ®Google Scholar
• BLINDAUER K, SHOULSON I, OAKES D et al.: Parkinson Study Group: a randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch. Neurol. (2006) 63:210-216.
   Google Scholar
• JOHNSTON TH, BROTCHIE JM: Drugs in development for Parkinson’s disease: an update. Curr. Opin. Investing. Drugs (2006) 7:25-32.
   Web of Science ®Google Scholar
• JENNER P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opin. Investig. Drugs (2005) 14:729-738.
   Google Scholar
• HAUSER RA, SCHWARZSCHILD MA. Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience. Drugs Aging (2005) 22:471-482.
   PubMed Web of Science ®Google Scholar
• STOCCHI F, ARNOLD G, ONOFRJ M et al.: Improvement of motor function in early Parkinson disease by safinamide. Neurology (2004) 63(4):746-748.
   PubMed Web of Science ®Google Scholar
• KONITSIOTIS S, BLANCHET PJ, VERHAGEN L et al.: AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology (2000) 54:1589-1595.
   PubMed Web of Science ®Google Scholar
• BARA-JIMENEZ W, DIMITROVA T, SHERZAI A et al.: Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson’s disease. Mov. Disord. (2004) 19:1183-1186.
   PubMed Web of Science ®Google Scholar
• DORAISWAMY PM, XIONG GL: Pharmacological strategies for the prevention of Alzheimer's disease. Expert Opin. Pharmacother. (2006) 7(1):1-10.
   Google Scholar
• HIMEDA T, KADOGUCHI N, KAMIYAMA Y et al.: Neuroprotective effect of arundic acid, an astrocyte-modul- ating agent, in mouse brain against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydro- pyridine) neurotoxicity. Neuropharmacology (2006) 50:329-344.
   PubMed Web of Science ®Google Scholar
• OLANOW CW, DAMIER P, GOETZ CG et al.: Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin. Neuropharmacol. (2004) 27:58-62.
   Google Scholar
• SAVOLA JM, HILL M, ENGSTROM M et al.: Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord. (2003) 18:872-883.
   PubMed Web of Science ®Google Scholar
• HADJ TAHAR A, GREGOIRE L, DARRE A et al.: Effect of a selective glutamate antagonist on l-DOPA-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiol. Dis. (2004) 15:171-176.
   Google Scholar
• LANG AE, GILL S, PATEL NK et al.: Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. (2006) 59:459-466.
   Google Scholar
• SODERSTROM K, O'MALLEY J, STEECE-COLLIER K et al.: Neural repair strategies for Parkinson's disease: insights from primate models. Cell Transplant. (2006) 15:251-265.
   PubMed Web of Science ®Google Scholar
• CLIFFORD JJ, DRAGO J, NATOLI AL et al.: Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease. Neuroscience (2002)109:81-88.
   Google Scholar
• ASANO T, MORI T, SHIMODA T et al.: Arundic acid (ONO-2506) ameliorates delayed ischemic brain damage by preventing astrocytic overproduction of S100B. Curr. Drug Targets CNS Neurol. Disord. (2005) 4:127-142.
   Web of Science ®Google Scholar
• ORRELL RW: AEOL-10150 (Aeolus). Curr. Opin. Investig. Drugs (2006) 7:70-80.
   Web of Science ®Google Scholar
• MAPLES KR, GREEN AR, FLOYD RA: Nitrone-related therapeutics: potential of NXY-059 for the treatment of acute ischaemic stroke. CNS Drugs (2004) 18:1071-1084.
   PubMed Web of Science ®Google Scholar
• DAVIS S: Optimising clinical trial design for proof of neuroprotection in acute ischaemic stroke: The SAINT Clinical Trial Programme. Cerebrovasc. Dis. (2006) 22(Suppl. 1):18-24.
   Web of Science ®Google Scholar
• VAN BERCKEL BN, KEGELES LS, WATERHOUSE R et al.: Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography. Neuropsychopharmacology (2006) 31:967-977.
   PubMed Web of Science ®Google Scholar
• JONG YJ, KUMAR V, KINGSTON AE et al.: Functional metabotropic glutamate receptors on nuclei from brain and primary cultured striatal neurons. Role of transporters in delivering ligand. J. Biol. Chem. (2005) 280(34):30469-30480.
   PubMed Web of Science ®Google Scholar
• LIU F, GONG X, MARQUIS K et al.: The inhibition of glycogen synthase kinase 3β by metabotropic glutamate receptor 5 mediated pathway confers neuroprotection to Aβ peptides. J. Neurochem. (2005) 95:1363-1372.
   Google Scholar
• EREMIN KO, KUDRIN VS, SARANSAARI P et al.: Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem. Res. (2005) 30:1493-500.
   Google Scholar
• KIMURA T, SUGIMORI M, LLINAS RR: Purkinje cell long-term depression is prevented by T-588, a neuroprotective compound that reduces cytosolic calcium release from intracellular stores. Proc. Natl. Acad. Sci. USA (2005) 102:17160-17165.
   Google Scholar
• GONZALEZ DENISELLE MC, GONZALEZ SL, DE NICOLA AF: Cellular basis of steroid neuroprotection in the wobbler mouse, a genetic model of motoneuron disease. Cell. Mol. Neurobiol. (2001) 21:237-254.
   Web of Science ®Google Scholar
• FERZAZ B, BRAULT E, BOURLIAUD G et al.: SSR180575 (7-chloro-N,N,5- trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide), a peripheral benzodiazepine receptor ligand, promotes neuronal survival and repair. J. Pharmacol. Exp. Ther. (2002) 301:1067-1078.
   Google Scholar
• NIRMALANANTHAN N, GREENSMITH L: Amyotrophic lateral sclerosis: recent advances and future therapies. Curr. Opin. Neurol. (2005) 18:712-719.
   Web of Science ®Google Scholar
• ZEMKE D, MAJID A: The potential of minocycline for neuroprotection in human neurologic disease. Clin. Neuropharmacol. (2004) 27:293-298.
   Google Scholar
• AISEN PS: The development of anti-amyloid therapy for Alzheimer's disease: from secretase modulators to polymerisation inhibitors. CNS Drugs (2005) 19:989-996.
   PubMed Web of Science ®Google Scholar
• CACABELOS R: Pharmacogenomics and therapeutic prospects in Alzheimer's disease. Expert Opin. Pharmacother. (2005) 6:1967-1987.
   Google Scholar
• HANNAN AJ: Novel therapeutic targets for Huntington's disease. Expert Opin. Ther. Targets (2005) 9:639-650.
   Google Scholar
• VAMECQ J, LATRUFFE N: Medical significance of peroxisome proliferator-activated receptors. Lancet (1999) 354:141-148.
   PubMed Web of Science ®Google Scholar